Nanochannel Technology for Constant Delivery of Chemotherapeutics: Beyond Metronomic Administration
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The purpose of this study is to demonstrate the long-term, controlled, zero-order release of low- and high-molecular weight chemotherapeutics through nanochannel membranes by exploiting the molecule-to-surface interactions presented by nanoconfinement.
Silicon membranes were produced with nanochannels of 5, 13 and 20 nm using standardized industrial microfabrication techniques. The study of the diffusion kinetics of interferonα-2b and leuprolide was performed by employing UV diffusion chambers. The released amount in the sink reservoir was monitored by UV absorbance.
Continuous zero-order release was demonstrated for interferonα-2b and leuprolide at release rates of 20 and 100 μg/day, respectively. The release rates exhibited by these membranes were verified to be in ranges suitable for human therapeutic applications.
Our membranes potentially represent a viable nanotechnological approach for the controlled administration of chemotherapeutics intended to improve the therapeutic efficacy of treatment and reduce many of the side effects associated with conventional drug administration.
- American Cancer Society. Cancer facts & figures 2009. Atlanta: American Cancer Society; 2009.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. CrossRef
- World Breast Cancer Therapeutics Markets. Frost and Sullivan; 2005.
- Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037–47. CrossRef
- Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin Cancer Res. 2005;11:4136–43. CrossRef
- Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3:16–20. CrossRef
- Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161–71. CrossRef
- Carmo VAS, Ferrari CS, Reis ECO, Ramaldes GA, Pereira MA, De Oliveira MC, et al. Biodistribution study and identification of inflammation sites using 99mTc-labelled stealth pH-sensitive liposomes. Nucl Med Commun. 2008;29:33–8. CrossRef
- Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol. 2010;28:181–8.
- Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83:761–9. CrossRef
- Baselt RC. Disposition of toxic drugs and chemicals in man. Biomedical Publications; 2008.
- Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol. 2002;13:12. CrossRef
- Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–36. CrossRef
- Hrushesky W. Circadian timing of cancer chemotherapy. Science 1985;228:73–5. CrossRef
- Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007;59:828–51. CrossRef
- Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008;14:485–93. CrossRef
- Wagner V, Dullaart A, Bock A, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24:1211–7. CrossRef
- Zafar Razzacki S, Thwar PK, Yang M, Ugaz VM, Burns MA. Integrated microsystems for controlled drug delivery. Adv Drug Deliv Rev. 2004;56:185–98. CrossRef
- Nuxoll EE, Siegel RA. BioMEMS devices for drug delivery. IEEE Eng Med Biol Mag. 2009;28:31–9. CrossRef
- Voskerician G, Shive MS, Shawgo RS, Recum HV, Anderson JM, Cima MJ, et al. Biocompatibility and biofouling of MEMS drug delivery devices. Biomaterials 2003;24:1959–67. CrossRef
- Ziaie B, Baldi A, Lei M, Gu Y, Siegel RA. Hard and soft micromachining for BioMEMS: review of techniques and examples of applications in microfluidics and drug delivery. Adv Drug Deliv Rev. 2004;56:145–72. CrossRef
- Dash AK, Cudworth II GC. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Meth. 1998;40:1–12. CrossRef
- Staples M, Daniel K, Cima M, Langer R. Application of micro- and nano-electromechanical devices to drug delivery. Pharm Res. 2006;23:847–63. CrossRef
- Langer R. New methods of drug delivery. Science 1990;249:1527–33. CrossRef
- Wright JC, Tao Leonard S, Stevenson CL, Beck JC, Chen G, Jao RM, et al. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J Control Release. 2001;75:1–10. CrossRef
- Santini Jr JT, Richards AC, Scheidt R, Cima MJ, Langer R. Microchips as controlled drug-delivery devices. Angew Chem Int Ed. 2000;39:2396–407. CrossRef
- Santini JT, Cima MJ, Langer R. A controlled-release microchip. Nature 1999;397:335–8. CrossRef
- Prescott JH, Lipka S, Baldwin S, Sheppard NF, Maloney JM, Coppeta J, et al. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotechnol. 2006;24:437–8. CrossRef
- Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, et al. Antitumor effects in mice of low-dose (Metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002;62:2731–5.
- Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045–7. CrossRef
- Chu WH, Ferrari M. In: Microrobotics and micromechanical systems, vol. 2593; SPIE: Philadelphia, PA, USA; 1995. p. 9–20.
- Desai TA, Chu WH, Tu JK, Beattie GM, Hayek A, Ferrari M. Microfabricated immunoisolating biocapsules. Biotechnol Bioeng. 1998;57:118–20. CrossRef
- Martin F, Walczak R, Boiarski A, Cohen M, West T, Cosentino C, et al. Tailoring width of microfabricated nanochannels to solute size can be used to control diffusion kinetics. J Control Release. 2005;102:123–33. CrossRef
- Cosentino C, Amato F, Walczak R, Boiarski A, Ferrari M. Dynamic model of biomolecular diffusion through two-dimensional nanochannels. J Phys Chem B. 2005;109:7358–64. CrossRef
- Kasemo B. Biocompatibility of titanium implants: surface science aspects. J Prosthet Dent. 1983;49:832–7. CrossRef
- Walczak R, Boiarski A, Cohen M, West T, Melnik K, Shapiro J, et al. Long-term biocompatibility of NanoGATE drug delivery implant. NanoBioTechnology 2005;1:35–42. CrossRef
- Lesinski GB, Sharma S, Varker KA, Sinha P, Ferrari M, Carson WE. Release of biologically functional interferon-alpha from a nanochannel delivery system. Biomed Microdevices. 2005;7:71–9. CrossRef
- Falkson C, Falkson G, Falkson H. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol. 1991;9:1403–8.
- Rai KR, Davey F, Peterson B, Schiffer C, Silver RT, Ozer H, et al. Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia 1995;9:1116–20.
- Tamayo L, Ortiz DM, Orozco-Covarrubias L, Duran-McKinster C, Mora MA, Avila E, et al. Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas. Arch Dermatol. 1997;133:1567–71. CrossRef
- Cersosimo R, Carr D. Prostate cancer: current and evolving strategies. Am J Health Syst Pharm. 1996;53:381–96.
- Rao G, Miller D. Clinical applications of hormonal therapy in ovarian cancer. Curr Treat Options Oncol. 2005;6:97–102. CrossRef
- Harvey HA, Lipton A, Max DT, Pearlman HG, Diaz-Perches R, de la Garza J. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J Clin Oncol. 1985;3:1068–72.
- Grattoni A, Rosa ED, Ferrati S, Wang Z, Gianesini A, Liu X, et al. Analysis of a nanochanneled membrane structure through convective gas flow. J Micromechanics Microengineering. 2009;19:115018. CrossRef
- Wills PR, Georgalis Y. Concentration dependence of the diffusion coefficient of a dimerizing protein. Bovine pancreatic trypsin inhibitor. J Phys Chem. 1981;85:3978–84. CrossRef
- Fioroni M, Diaz MD, Burger K, Berger S. Solvation phenomena of a tetrapeptide in water/trifluoroethanol and water/ethanol mixtures: a diffusion NMR, intermolecular NOE, and molecular dynamics study. J Am Chem Soc. 2002;124:7737–44. CrossRef
- Burke DC. The purification of interferon. Biochem J. 1961;78:556–63.
- Sharma S, Nijdam AJ, Sinha PM, Walczak RJ, Liu X, Cheng MM, et al. Controlled-release microchips. Expert Opin Drug Deliv. 2006;3:379–94. CrossRef
- Danckwerts M, Fassihi A. Implantable controlled release drug delivery systems: a review. Drug Dev Ind Pharm. 1991;17:1465. CrossRef
- Velez G, Whitcup SM. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol. 1999;83:1225–9. CrossRef
- Narasimhan B, Langer R. Zero-order release of micro- and macromolecules from polymeric devices: the role of the burst effect. J Control Release. 1997;47:13–20. CrossRef
- Brizzi M, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network. BMC Cancer. 2009;9:388. CrossRef
- John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007;298:2869–76. CrossRef
- Nanochannel Technology for Constant Delivery of Chemotherapeutics: Beyond Metronomic Administration
Volume 28, Issue 2 , pp 292-300
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- controlled release
- drug delivery
- Industry Sectors
- Author Affiliations
- 1. Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA
- 2. NanoMedical Systems, Inc., Austin, Texas, USA
- 3. Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
- 4. Department of Bioengineering, Rice University, Houston, Texas, USA
- 5. 1825 Pressler St. Suite 537, Houston, Texas, 77030, USA